Skip to main content
Psychedex
Sources
38
11 strong · 19 moderate · 8 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
101
74verified7partial20inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
May 3, 2026 · pipeline-v5
Values approved
132/132 (100%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold25 mg25 mglow
Low50–100 mg50–100 mglow
Common100–200 mg100–200 mglow
Strong200–300 mg200–300 mglow
Heavy300+ mg300+ mglow
Editorial

Dose ranges from existing database seed data (originally community-curated). No controlled human dosing studies exist for methcathinone. Values are broadly plausible given methcathinone's approximately 2x potency over amphetamine in rat drug discrimination (ED50 0.37 vs 0.71 mg/kg, Glennon et al. 1987), but have no verifiable primary source in the published literature. Flagged for editorial review as safety-critical unverified data.

Reasoning

Dose ranges from existing database seed data (originally community-curated). No controlled human dosing studies exist for methcathinone. Values are broadly plausible given methcathinone's approximately 2x potency over amphetamine in rat drug discrimination (ED50 0.37 vs 0.71 mg/kg, Glennon et al. 1987), but have no verifiable primary source in the published literature. Flagged for editorial review as safety-critical unverified data.

Evidence basis: community_consensus_large

insufflatedtrace

FieldPublishedAI ProposedConfidence
Threshold15 mg15 mglow
Low25–50 mg25–50 mglow
Common50–100 mg50–100 mglow
Strong100–200 mg100–200 mglow
Heavy200+ mg200+ mglow
Editorial

Insufflation is documented as a common ROA in review literature (Kelly 2011, Prosser & Nelson 2011). Dose ranges inferred from oral values with typical insufflation bioavailability adjustment (~60-80% of oral doses) based on amphetamine-class pharmacology. No published insufflation dose data exist for methcathinone. All values require editorial verification.

Reasoning

Insufflation is documented as a common ROA in review literature (Kelly 2011, Prosser & Nelson 2011). Dose ranges inferred from oral values with typical insufflation bioavailability adjustment (~60-80% of oral doses) based on amphetamine-class pharmacology. No published insufflation dose data exist for methcathinone. All values require editorial verification.

Evidence basis: structural_analogy

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace15–30 minutes15–30 minuteslow
Editorial

Inferred from amphetamine-class oral onset (15-30 minutes). Rat data show i.p. onset within 5 minutes (Young & Glennon 1998), but oral onset in humans would be slower due to GI absorption. No human oral onset data published.

Reasoning

Inferred from amphetamine-class oral onset (15-30 minutes). Rat data show i.p. onset within 5 minutes (Young & Glennon 1998), but oral onset in humans would be slower due to GI absorption. No human oral onset data published.

Evidence basis: structural_analogy

Come uptrace15–30 minutes15–30 minuteslow
Editorial

Estimated from amphetamine-class come-up profile. No substance-specific human data.

Reasoning

Estimated from amphetamine-class come-up profile. No substance-specific human data.

Evidence basis: structural_analogy

Peaktrace1–2 hours1–2 hourslow
Editorial

Estimated from amphetamine-class peak duration and unverified seed data suggesting 4-6 hour total duration. Peak likely occupies 1-2 hours of the total experience.

Reasoning

Estimated from amphetamine-class peak duration and unverified seed data suggesting 4-6 hour total duration. Peak likely occupies 1-2 hours of the total experience.

Evidence basis: structural_analogy

Offsettrace1–2 hours1–2 hourslow
Editorial

Estimated from amphetamine-class offset profile. No substance-specific data.

Reasoning

Estimated from amphetamine-class offset profile. No substance-specific data.

Evidence basis: structural_analogy

Totaltrace4–6 hours4–6 hourslow
Editorial

From existing database seed data. Consistent with stimulant class duration and methcathinone's potency relative to amphetamine, but no controlled human pharmacokinetic study confirms this estimate. Rat discriminative stimulus lasts 60-90 minutes i.p. (Young & Glennon 1998), which would extrapolate to a longer oral human duration.

Reasoning

From existing database seed data. Consistent with stimulant class duration and methcathinone's potency relative to amphetamine, but no controlled human pharmacokinetic study confirms this estimate. Rat discriminative stimulus lasts 60-90 minutes i.p. (Young & Glennon 1998), which would extrapolate to a longer oral human duration.

Evidence basis: community_consensus_large

After effectstrace4–12 hours4–12 hourslow
Editorial

Stimulant class aftereffects (fatigue, anhedonia, disrupted sleep) typically persist 4-12 hours beyond subjective offset. No methcathinone-specific data.

Reasoning

Stimulant class aftereffects (fatigue, anhedonia, disrupted sleep) typically persist 4-12 hours beyond subjective offset. No methcathinone-specific data.

Evidence basis: structural_analogy

insufflated

FieldPublishedAI ProposedConfidence
Onsettrace5–10 minutes5–10 minuteslow
Editorial

Insufflation onset inferred from amphetamine/stimulant class. Faster than oral due to nasal mucosal absorption. No published data for methcathinone insufflation onset.

Reasoning

Insufflation onset inferred from amphetamine/stimulant class. Faster than oral due to nasal mucosal absorption. No published data for methcathinone insufflation onset.

Evidence basis: structural_analogy

Totaltrace3–5 hours3–5 hourslow
Editorial

Insufflated duration typically shorter than oral for stimulants. Estimated as approximately 75-85% of oral total duration. No published data.

Reasoning

Insufflated duration typically shorter than oral for stimulants. Estimated as approximately 75-85% of oral total duration. No published data.

Evidence basis: structural_analogy

After effectstrace4–12 hours4–12 hourslow
Editorial

Stimulant class aftereffects similar regardless of ROA. No methcathinone-specific data.

Reasoning

Stimulant class aftereffects similar regardless of ROA. No methcathinone-specific data.

Evidence basis: structural_analogy

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutemoderatemoderatemedium
Chronichighhighmedium
Organs Affectedcardiovascular, central_nervous_system, basal_gangliacardiovascular, central_nervous_system, basal_gangliamedium
Editorial

Acute toxicity classified as moderate: LD50 data exist only in mice (201.7 mg/kg i.p., Asser et al. 2019) with seizure liability, but no human overdose deaths attributed solely to pure methcathinone are documented. Chronic toxicity classified as high: direct human PET evidence of persistent DAT loss (McCann et al. 1998, n=4), animal evidence of both dopaminergic and serotonergic neurotoxicity (Sparago et al. 1996), and rat PFC damage (Zhou et al. 2025). The IV/manganese parkinsonism literature further elevates chronic risk for that route. Chronic rating not discounted because human PET data (though small n) provide substance-specific evidence.

Reasoning

Acute toxicity classified as moderate: LD50 data exist only in mice (201.7 mg/kg i.p., Asser et al. 2019) with seizure liability, but no human overdose deaths attributed solely to pure methcathinone are documented. Chronic toxicity classified as high: direct human PET evidence of persistent DAT loss (McCann et al. 1998, n=4), animal evidence of both dopaminergic and serotonergic neurotoxicity (Sparago et al. 1996), and rat PFC damage (Zhou et al. 2025). The IV/manganese parkinsonism literature further elevates chronic risk for that route. Chronic rating not discounted because human PET data (though small n) provide substance-specific evidence.

Evidence basis: animal_study

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicallowlowmedium
Psychologicalhighhighmedium
Compulsive Redosinghighhighmedium
Dose Escalationmoderatemoderatemedium
Editorial

Psychological dependence rated high based on: documented compulsive use patterns in Eastern European epidemic (Myśliwka et al. 2011), high DAT/NET selectivity predicting abuse potential (Negus & Banks 2017), robust ICSS facilitation (Davies et al. 2020). Physical dependence rated low: no substance-specific withdrawal data, but stimulant-class withdrawal expected. Compulsive redosing rated high based on epidemic literature and pharmacological profile.

Reasoning

Psychological dependence rated high based on: documented compulsive use patterns in Eastern European epidemic (Myśliwka et al. 2011), high DAT/NET selectivity predicting abuse potential (Negus & Banks 2017), robust ICSS facilitation (Davies et al. 2020). Physical dependence rated low: no substance-specific withdrawal data, but stimulant-class withdrawal expected. Compulsive redosing rated high based on epidemic literature and pharmacological profile.

Evidence basis: published_case_series

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitymildmildlow
Symptomsfatigue, anhedonia, depression, hypersomnia, increased appetite, irritabilityfatigue, anhedonia, depression, hypersomnia, increased appetite, irritabilitylow
FatalNoNolow
Medical SupervisionNot requiredNot requiredlow
Editorial

No substance-specific withdrawal characterization exists for methcathinone. Withdrawal profile inferred entirely from stimulant class (amphetamine/methamphetamine withdrawal). Symptoms and timeline are class-level estimates. Stimulant withdrawal is not life-threatening but can be psychologically distressing.

Reasoning

No substance-specific withdrawal characterization exists for methcathinone. Withdrawal profile inferred entirely from stimulant class (amphetamine/methamphetamine withdrawal). Symptoms and timeline are class-level estimates. Stimulant withdrawal is not life-threatening but can be psychologically distressing.

Evidence basis: published_case_series

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupmoderatemoderatelow
Half-life——low
Full Reset——low
Cross-tolerances——low
Editorial

Tolerance buildup rated moderate based on rat ICSS data showing complex tolerance/sensitization dynamics with repeated methcathinone (Suyama et al. 2019) and amphetamine-class inference. No substance-specific human tolerance data exist.

Reasoning

Tolerance buildup rated moderate based on rat ICSS data showing complex tolerance/sensitization dynamics with repeated methcathinone (Suyama et al. 2019) and amphetamine-class inference. No substance-specific human tolerance data exist.

Evidence basis: animal_study

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
cardiovascular severe cardiovascular diseasetraceabsoluteabsolutemedium
Editorial

Class-level contraindication for all catecholaminergic releasing agents. Methcathinone's NET substrate activity (EC50 ~50 nM) produces substantial norepinephrine release. No substance-specific cardiovascular contraindication studies exist.

Reasoning

Class-level contraindication for all catecholaminergic releasing agents. Methcathinone's NET substrate activity (EC50 ~50 nM) produces substantial norepinephrine release. No substance-specific cardiovascular contraindication studies exist.

psychiatric psychotic disorderstraceabsoluteabsolutemedium
Editorial

Supported by review literature documenting paranoia and hallucinations with heavy methcathinone use (Debruyne et al. 2014, Kelly 2011). Class-level contraindication for all DAT-releasing stimulants. No substance-specific psychiatric contraindication study.

Reasoning

Supported by review literature documenting paranoia and hallucinations with heavy methcathinone use (Debruyne et al. 2014, Kelly 2011). Class-level contraindication for all DAT-releasing stimulants. No substance-specific psychiatric contraindication study.

other concurrent MAOI therapytraceabsoluteabsolutehigh
Editorial

Well-established class-level contraindication for all monoamine releasing agents combined with MAOIs. No methcathinone-specific case report, but the pharmacological mechanism is unambiguous.

Reasoning

Well-established class-level contraindication for all monoamine releasing agents combined with MAOIs. No methcathinone-specific case report, but the pharmacological mechanism is unambiguous.

psychiatric bipolar disordertracerelativerelativelow
Editorial

Class-level contraindication for catecholaminergic stimulants. No methcathinone-specific data.

Reasoning

Class-level contraindication for catecholaminergic stimulants. No methcathinone-specific data.

cardiovascular long QT syndrometraceabsoluteabsolutelow
Editorial

Class-level contraindication for sympathomimetic stimulants. No methcathinone-specific cardiac electrophysiology data.

Reasoning

Class-level contraindication for sympathomimetic stimulants. No methcathinone-specific cardiac electrophysiology data.

pregnancy breastfeeding pregnancytraceabsoluteabsolutelow
Editorial

No substance-specific reproductive data. Class-level absolute contraindication for sympathomimetic stimulants during pregnancy.

Reasoning

No substance-specific reproductive data. Class-level absolute contraindication for sympathomimetic stimulants during pregnancy.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Come uptrace900–1800 sec(i=0.30)900–1800 sec(i=0.30)low
Editorial

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Reasoning

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Onsettrace900–1800 sec(i=0.05)900–1800 sec(i=0.05)low
Editorial

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Reasoning

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Peaktrace3600–7200 sec(i=1.00)3600–7200 sec(i=1.00)low
Editorial

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Reasoning

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Plateautrace3600–5400 sec(i=0.50)3600–5400 sec(i=0.50)low
Editorial

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Reasoning

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Resolutiontrace3600–7200 sec(i=0.20)3600–7200 sec(i=0.20)low
Editorial

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Reasoning

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Afterglowtrace14400–43200 sec(i=0.05)14400–43200 sec(i=0.05)low
Editorial

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Reasoning

No controlled human pharmacokinetic or duration data exist for oral methcathinone. Timeline inferred from: (1) unverified seed data estimating 4\u20136 hour total oral duration; (2) rat discriminative stimulus duration of 60\u201390 minutes (i.p., Young & Glennon 1998), which does not translate directly to oral human kinetics; (3) amphetamine-class pharmacology with methcathinone being ~2\u00d7 more potent. Onset and phase durations are class-level estimates. All values require editorial verification.

Dose Tier Summaries

thresholdtrace
low

At threshold doses, effects are subtle and easily attributed to placebo: a mild increase in alertness, slight mood elevation, and faint physical energy. Cognitive effects are minimal — perhaps a slight quickening of thought or enhanced motivation that does not clearly distinguish itself from a good night's sleep or a cup of coffee. Physically, mild pupil dilation and a slight increase in heart rate may be noticeable to the attentive user. Appetite suppression is negligible. Sleep is unlikely to be significantly disrupted if the dose is taken early in the day.

Editorial

No controlled human dosing data exist for methcathinone at any dose. Threshold effects inferred from amphetamine class pharmacology (DAT/NET releasing agent ~2× potency of amphetamine in animal models). Brief seed data suggest threshold ~25 mg oral, but this value is unverified.

Reasoning

No controlled human dosing data exist for methcathinone at any dose. Threshold effects inferred from amphetamine class pharmacology (DAT/NET releasing agent ~2× potency of amphetamine in animal models). Brief seed data suggest threshold ~25 mg oral, but this value is unverified.

Evidence basis: structural_analogy

lighttrace
low

At light doses, stimulation becomes clearly perceptible: increased wakefulness, mild euphoria, enhanced motivation, and a sense of confidence and sociability. Thought acceleration is noticeable but manageable. Focus enhancement may be present, allowing sustained attention on tasks. Physical effects include elevated heart rate, mild vasoconstriction with cool extremities, slight jaw tension, and reduced appetite. The experience is functionally manageable — most users would be able to carry out routine tasks. Sleep will be difficult for several hours after dosing.

Editorial

Inferred from amphetamine-class pharmacology and unverified seed data suggesting light range of 50–100 mg oral. Review literature describes desired effects of increased energy, euphoria, and confidence at recreational doses. No controlled human dose-response data exist.

Reasoning

Inferred from amphetamine-class pharmacology and unverified seed data suggesting light range of 50–100 mg oral. Review literature describes desired effects of increased energy, euphoria, and confidence at recreational doses. No controlled human dose-response data exist.

Evidence basis: structural_analogy

commontrace
low

At common doses, the full stimulant experience is present: pronounced cognitive euphoria, strong motivation enhancement, marked thought acceleration, and significant wakefulness. Sociability and confidence are heightened. Users report increased energy and reduced fatigue, with a clear sense of stimulation that dominates the experience. Cardiovascular effects become prominent — tachycardia, noticeable vasoconstriction, and elevated blood pressure. Bruxism (jaw clenching), excessive sweating, and appetite suppression are typical. Compulsive redosing urge may emerge as effects begin to wane. Sleep is impossible for the duration and several hours beyond. Functional impairment increases due to overconfidence and reduced impulse control despite subjective feelings of enhanced performance.

Editorial

Inferred from amphetamine-class pharmacology and unverified seed data suggesting common range of 100–200 mg oral. Review literature (Debruyne et al. 2014, Kelly 2011) documents euphoria, energy, bruxism, sweating, and compulsive redosing at recreational doses. No controlled human dose-response data exist.

Reasoning

Inferred from amphetamine-class pharmacology and unverified seed data suggesting common range of 100–200 mg oral. Review literature (Debruyne et al. 2014, Kelly 2011) documents euphoria, energy, bruxism, sweating, and compulsive redosing at recreational doses. No controlled human dose-response data exist.

Evidence basis: structural_analogy

strongtrace
low

At strong doses, stimulation is intense and potentially overwhelming: powerful euphoria gives way to agitation and anxiety in many users. Thought acceleration may become dysphoric — racing thoughts, paranoid ideation, and difficulty maintaining coherent conversation. The compulsive redosing urge is strong. Cardiovascular stress is significant — pronounced tachycardia, hypertension, and vasoconstriction. Bruxism becomes uncomfortable, sweating is profuse, and tremor may appear. Body temperature may rise. Anorexia is complete. Sleep is impossible for many hours. The comedown is harsh, with marked anhedonia, irritability, and depression. Risk of psychiatric adverse effects (paranoia, hallucinations) increases substantially at this range.

Editorial

Inferred from amphetamine-class pharmacology and unverified seed data suggesting strong range of 200–300 mg oral. Review literature documents agitation, anxiety, paranoia, and hallucinations with heavy use. No controlled human dose-response data exist.

Reasoning

Inferred from amphetamine-class pharmacology and unverified seed data suggesting strong range of 200–300 mg oral. Review literature documents agitation, anxiety, paranoia, and hallucinations with heavy use. No controlled human dose-response data exist.

Evidence basis: structural_analogy

heavytrace
low

At heavy doses, the experience is dominated by adverse effects. Any residual euphoria is overshadowed by severe anxiety, paranoia, and potential hallucinations. Psychomotor agitation is extreme. Rational decision-making is severely impaired, and compulsive redosing may lead to dangerous cumulative dosing. Cardiovascular emergency risk is elevated — severe tachycardia, dangerous hypertension, and risk of cardiac arrhythmia. Seizures are possible based on animal data showing epileptic seizures at high doses. Hyperthermia becomes a concern, particularly with physical activity or warm environments. The subsequent crash involves profound anhedonia, depression, exhaustion, and extended sleep disruption. Repeated heavy dosing carries the highest risk of neurotoxicity based on animal evidence of dopaminergic and serotonergic damage.

Editorial

Inferred from amphetamine-class pharmacology and animal toxicity data (Asser et al. 2019: seizures in 74% of mice at high doses). Unverified seed data suggest heavy threshold at 300+ mg oral. Review literature documents severe psychiatric and cardiovascular adverse effects with heavy/chronic use. No controlled human dose-response data exist.

Reasoning

Inferred from amphetamine-class pharmacology and animal toxicity data (Asser et al. 2019: seizures in 74% of mice at high doses). Unverified seed data suggest heavy threshold at 300+ mg oral. Review literature documents severe psychiatric and cardiovascular adverse effects with heavy/chronic use. No controlled human dose-response data exist.

Evidence basis: structural_analogy

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

11 strong · 19 moderate · 8 weak
  1. [1]
    strong
    Methcathinone: a new and potent amphetamine-like agent.
    Glennon RA, Yousif M, Naiman N, Kalix P · 1987 · Pharmacology, Biochemistry, and Behavior
    pubmed 35753695 claims checked3 verified2 partial
  2. [2]
    weak
    Synthetic cathinones: an updated harms assessment (GOV.UK, ACMD)
    Advisory Council on the Misuse of Drugs (ACMD) · 2023
    linkno claims checked
  3. [3]
    moderate
    Cathinone derivatives: a review of their chemistry, pharmacology and toxicology.
    Kelly JP · 2011 · Drug Testing and Analysis
    doi.org/10.1002/dta.313pubmed 217556076 claims checked1 verified5 inconclusive
  4. [4]
    weak
    Methcathinone DEA Emergency Scheduling (58 FR 25934)
    Drug Enforcement Administration · 1993
    linkno claims checked
  5. [5]
    moderate
    Pharmacological characterization of designer cathinones in vitro
    Simmler LD, Buser TA, Donzelli M, et al. · 2012 · British Journal of Pharmacology
    doi.org/10.1111/j.1476-5381.2012.02145.x8 claims checked6 verified2 inconclusive
  6. [6]
    strong
    Investigation of the Optical Isomers of Methcathinone, and Two Achiral Analogs, at Monoamine Transporters and in Intracranial Self-Stimulation Studies in Rats.
    Davies RA, Baird TR, Nguyen VT, Ruiz B, Sakloth F, Eltit JM, Negus SS, Glennon RA · 2020 · ACS Chemical Neuroscience
    doi.org/10.1021/acschemneuro.9b00617pubmed 323569617 claims checked6 verified1 inconclusive
  7. [7]
    strong
    In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates.
    Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA · 2003 · Journal of Pharmacology and Experimental Therapeutics
    pubmed 129547962 claims checked2 verified
  8. [8]
    moderate
    Emerging drugs of abuse: current perspectives on substituted cathinones
    Debruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J · 2014 · Substance Abuse and Rehabilitation
    doi.org/10.2147/sar.s37257pubmed 249667132 claims checked2 verified
  9. [9]
    moderate
    Manganese-Induced Parkinsonism due to Ephedrone Abuse.
    Sikk K, Haldre S, Aquilonius SM, Taba P · 2011 · Parkinson's Disease
    doi.org/10.4061/2011/865319pubmed 214039093 claims checked3 verified
  10. [10]
    moderate
    Manganese and Parkinson's Disease: A Critical Review and New Findings.
    Guilarte TR · 2010 · Environmental Health Perspectives
    doi.org/10.1289/ehp.0901748pubmed 204037944 claims checked4 verified
  11. [11]
    strong
    Acute effects of methcathinone and manganese in mice: A dose response study.
    Asser A, Kõks S, Soomets U, Terasmaa A, Sauk M, Eltermaa M, Piip P, Ubhayasekera K, Bergquist J, Taba P · 2019 · Heliyon
    doi.org/10.1016/j.heliyon.2019.e02475pubmed 316875705 claims checked4 verified1 partial
  12. [12]
    moderate
    Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428
    McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA · 1998 · Journal of Neuroscience
    pubmed 97634842 claims checked1 verified1 partial
  13. [13]
    strong
    Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.
    Suyama JA, Banks ML, Negus SS · 2019 · Psychopharmacology
    doi.org/10.1007/s00213-018-5029-ypubmed 302325293 claims checked3 verified
  14. [14]
    weak
    Manganese toxicity with ephedrone abuse manifesting as parkinsonism: a case report.
    Iqbal M, Monaghan T, Redmond J · 2012 · Journal of Medical Case Reports
    doi.org/10.1186/1752-1947-6-52pubmed 223135121 claim checked1 inconclusive
  15. [15]
    strong
    Methcathinone ("cat"): an enantiomeric potency comparison.
    Glennon RA, Young R, Martin BR, Dal Cason TA · 1995 · Pharmacology, Biochemistry, and Behavior
    pubmed 76177073 claims checked2 verified1 inconclusive
  16. [16]
    moderate
    Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up.
    Sikk K, Haldre S, Aquilonius SM, Asser A, Paris M, Roose Ä, Petterson J, Eriksson SL, Bergquist J, Taba P · 2013 · European Journal of Neurology
    doi.org/10.1111/ene.12088pubmed 233473991 claim checked1 inconclusive
  17. [17]
    moderate
    The outcome of the movement disorder in methcathinone abusers: clinical, MRI and manganesemia changes, and neuropathology.
    Stepens A, Groma V, Skuja S, Platkajis A, Aldins P, Eksteina I, Martinsone I, Bricis R, Donaghy M · 2014 · European Journal of Neurology
    doi.org/10.1111/ene.12185pubmed 236788673 claims checked1 verified2 inconclusive
  18. [18]
    weak
    Encephalopathy caused by intravenous potassium permanganate used for illegal production of methcathinone (ephedrone) from medicines containing pseudoephedrine.
    Habrat B, Baran-Furga H, Sienkiewicz-Jarosz H, Sein Anand J, Poniatowska R · 2013 · Przeglad Lekarski
    pubmed 244667044 claims checked4 verified
  19. [19]
    weak
    Ephedron dependence--case report.
    Myśliwka D, Zuk M, Dziurkowski M · 2011 · Psychiatria Polska
    pubmed 216148344 claims checked3 verified1 inconclusive
  20. [20]
    strong
    Discriminative stimulus effects of S(-)-methcathinone (CAT): a potent stimulant drug of abuse.
    Young R, Glennon RA · 1998 · Psychopharmacology
    pubmed 98770048 claims checked5 verified1 partial2 inconclusive
  21. [21]
    weak
    Synthetic cathinones — UNODC substance group listing
    United Nations Office on Drugs and Crime · 2024
    linkno claims checked
  22. [22]
    moderate
    Decoding the Structure of Abuse Potential for New Psychoactive Substances: Structure-Activity Relationships for Abuse-Related Effects of 4-Substituted Methcathinone Analogs.
    Negus SS, Banks ML · 2017 · Current Topics in Behavioral Neurosciences
    doi.org/10.1007/7854_2016_18pubmed 276962172 claims checked2 verified
  23. [23]
    moderate
    Determination of Methcathinone in Urine by GC-MS.
    Liu DX, Zhao MM · 2017 · Fa Yi Xue Za Zhi (Journal of Forensic Medicine)
    doi.org/10.3969/j.issn.1004-5619.2017.05.012pubmed 292755562 claims checked2 verified
  24. [24]
    strong
    Identification and quantification of synthetic cathinones in blood and urine using liquid chromatography-quadrupole/time of flight (LC-Q/TOF) mass spectrometry
    Glicksberg L, Bryand K, Kerrigan S · 2016 · Journal of Chromatography B
    doi.org/10.1016/j.jchromb.2016.09.027pubmed 276977311 claim checked1 verified
  25. [25]
    strong
    Abuse-Related Neurochemical Effects of Para-Substituted Methcathinone Analogs in Rats: Microdialysis Studies of Nucleus Accumbens Dopamine and Serotonin.
    Suyama JA, Sakloth F, Kolanos R, Glennon RA, Lazenka MF, Negus SS, Banks ML · 2016 · Journal of Pharmacology and Experimental Therapeutics
    doi.org/10.1124/jpet.115.229559pubmed 266456385 claims checked4 verified1 partial
  26. [26]
    strong
    Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs.
    Cozzi NV, Brandt SD, Daley PF, Partilla JS, Rothman RB, Tulzer A, Sitte HH, Baumann MH · 2013 · European Journal of Pharmacology
    doi.org/10.1016/j.ejphar.2012.11.008pubmed 231785232 claims checked1 verified1 partial
  27. [27]
    moderate
    Methcathinone Neurotoxicity in the Rat Prefrontal Cortex by Integrated Synaptic Changes and Transcriptome Analysis.
    Zhou R, Xu Y, Xu C, Chen Z, Lv J, Yun K, Wei Z · 2025 · Addiction Biology
    doi.org/10.1111/adb.70113pubmed 414147083 claims checked3 verified
  28. [28]
    moderate
    Substituted methcathinones differ in transporter and receptor interactions
    Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A · 2013 · Biochemical Pharmacology
    doi.org/10.1016/j.bcp.2013.04.004pubmed 235834541 claim checked1 inconclusive
  29. [29]
    strong
    Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse.
    Sparago M, Wlos J, Yuan J, Hatzidimitriou G, Tolliver J, Dal Cason TA, Katz J, Ricaurte G · 1996 · Journal of Pharmacology and Experimental Therapeutics
    pubmed 89302153 claims checked2 verified1 inconclusive
  30. [30]
    moderate
    Analysis of a distinct speech disorder seen in chronic manganese toxicity following Ephedrone abuse.
    Selikhova M, Tripoliti E, Fedoryshyn L, Matvienko Y, Stanetska H, Boychuk M, Komnatska I, Lees AJ, Sanotsky Y · 2016 · Clinical Neurology and Neurosurgery
    doi.org/10.1016/j.clineuro.2016.05.027pubmed 273102891 claim checked1 verified
  31. [31]
    moderate
    Urine as a material for evaluation of exposure to manganese in methcathinone users.
    Golasik M, Wodowski G, Gomolka E, Herman M, Piekoszewski W · 2014 · Journal of Trace Elements in Medicine and Biology
    doi.org/10.1016/j.jtemb.2014.04.005pubmed 248676572 claims checked1 verified1 inconclusive
  32. [32]
    moderate
    Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism.
    Djamshidian A, Sanotsky Y, Matviyenko Y, O'Sullivan SS, Sharman S, Selikhova M, Fedoryshyn L, Filts Y, Bearn J, Lees AJ, Averbeck BB · 2013 · Addiction
    doi.org/10.1111/add.12080pubmed 232282081 claim checked1 verified
  33. [33]
    weak
    Characteristic of neuropsychological deficits in patients diagnosed with manganese encephalopathy due to ephedrone use - case series analysis.
    Kałwa A · 2020 · Psychiatria Polska
    doi.org/10.12740/pp/105420pubmed 327720661 claim checked1 verified
  34. [34]
    weak
    Evaluation of cognitive characteristics of patients developing manifestations of parkinsonism secondary to long-term ephedrone use.
    Koksal A, Keskinkilic C, Sozmen MV, Dirican AC, Aysal F, Altunkaynak Y, Baybas S · 2014 · European Neurology
    doi.org/10.1159/000356509pubmed 244576241 claim checked1 verified
  35. [35]
    moderate
    The Toxicology of Bath Salts: A Review of Synthetic Cathinones
    Prosser J, Nelson L · 2011 · Journal of Medical Toxicology
    doi.org/10.1007/s13181-011-0193-z1 claim checked1 inconclusive
  36. [36]
    moderate
    Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome.
    Juurmaa J, Menke RA, Vila P, Müürsepp A, Tomberg T, Ilves P, Nigul M, Johansen-Berg H, Donaghy M, Stagg CJ, Stepens A, Taba P · 2016 · Brain and Behavior
    pubmed 278436942 claims checked2 verified
  37. [37]
    moderate
    White matter abnormalities in methcathinone abusers with an extrapyramidal syndrome.
    Stepens A, Stagg CJ, Platkajis A, Boudrias MH, Johansen-Berg H, Donaghy M · 2010 · Brain
    doi.org/10.1093/brain/awq281pubmed 210369492 claims checked2 verified
  38. [38]
    moderate
    Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys.
    Smith DA, Negus SS, Poklis JL, Blough BE, Banks ML · 2017 · Addiction Biology
    doi.org/10.1111/adb.12399pubmed 27060605no claims checked
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary13 claims10verified2partial1inconclusive
verifiedIn amphetamine-trained rat drug discrimination, racemic methcathinone produces full generalization at ED₅₀ = 0.37 mg/kg (i.p.) — approximately twice as potent as racemic amphetamine (ED₅₀ = 0.71 mg/kg)[1]model confidence 99%
Verified

Abstract explicitly states ED50 = 0.37 mg/kg in amphetamine discrimination and notes it is more potent than amphetamine (0.71 mg/kg) — an exact numerical match.

ED50 = 0.37 mg/kg in amphetamine discrimination (more potent than amphetamine 0.71 mg/kg)

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveFirst synthesized in 1928 at Parke-Davis and briefly investigated as an antidepressant in the Soviet Union during the 1930s–1940s, methcathinone entered clandestine use in the USSR by the 1970s and appeared on the US illicit market in the late 1980s, prompting DEA Schedule I placement in 1992–1993[3]model confidence 60%
Inconclusive

Review paper covers methcathinone abuse history and legal status, but the abstract does not confirm any of the specific dates cited (1928 synthesis, 1930s–1940s antidepressant use, 1970s USSR clandestine use, 1992–1993 DEA scheduling). The data likely appears in the full text.

methcathinone longer abuse history from readily available starting materials; Legal status changes globally.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedMethcathinone acts as a monoamine transporter substrate (releasing agent), entering presynaptic terminals via DAT and NET to promote carrier-mediated efflux of dopamine and norepinephrine[5]model confidence 90%
Verified

Abstract confirms methcathinone acts as a preferential DA and NA uptake inhibitor and induces DA release, similar to amphetamine/methamphetamine, supporting the substrate/releasing-agent mechanism at DAT and NET.

Cathinone, methcathinone and flephedrone act as preferential DA and NA uptake inhibitors and induced release of DA, similar to amphetamine/methamphetamine.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedMethcathinone acts as a monoamine transporter substrate (releasing agent), entering presynaptic terminals via DAT and NET to promote carrier-mediated efflux of dopamine and norepinephrine[6]model confidence 98%
Verified

Abstract explicitly classifies MCAT isomers as transporter substrates at DAT and NET, directly confirming the substrate/releasing mechanism.

MCAT isomers are nearly equieffective at DAT and NET as transporter substrates

checked by claude-sonnet-4-6 · May 3, 2026

verifiedNET substrate activity occurs at EC₅₀ ~50 nM, with nearly equipotent DAT activity and ≥63-fold selectivity over SERT[7]model confidence 95%
Verified

Abstract confirms NET substrate activity at EC50 ~50 nM and DAT substrate activity. SERT selectivity figure is not in this abstract but the NET and DAT claims are fully confirmed.

methcathinone acts as substrate at NET (EC50 ~50 nM) and DAT, distinct from ephedrine-type compounds

checked by claude-sonnet-4-6 · May 3, 2026

verifiedNET substrate activity occurs at EC₅₀ ~50 nM, with nearly equipotent DAT activity and ≥63-fold selectivity over SERT[6]model confidence 98%
Verified

Abstract confirms nearly equieffective DAT and NET substrate activity and ≥63-fold lower potency at SERT, fully supporting this claim.

MCAT isomers are nearly equieffective at DAT and NET as transporter substrates; ≥63-fold less potent at SERT.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedReported effects include euphoria, increased energy, confidence, wakefulness, and compulsive redosing — consistent with its dopaminergic mechanism[8]model confidence 82%
Verified

Abstract confirms increased energy as a user-reported effect, and the review covers substituted cathinone effects broadly. The paper is clearly about the right topic; increased energy is explicitly mentioned.

increased energy, empathy, libido reported by users.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedReported effects include euphoria, increased energy, confidence, wakefulness, and compulsive redosing — consistent with its dopaminergic mechanism[3]model confidence 78%
Verified

Abstract describes methcathinone as having amphetamine-like effects, which encompasses the listed stimulant effects. Review covers the right topic.

amphetamine-like effects in vitro and in vivo albeit less potent

checked by claude-sonnet-4-6 · May 3, 2026

verifiedIntravenous administration of illicitly synthesized methcathinone — prepared by oxidizing pseudoephedrine with potassium permanganate — introduces manganese contamination causing permanent, levodopa-resistant parkinsonism[9]model confidence 97%
Verified

Abstract explicitly confirms levodopa-unresponsive parkinsonism arising within months of IV ephedrone (methcathinone) and manganese abuse.

Levodopa unresponsive parkinsonism within months of use.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedIntravenous administration of illicitly synthesized methcathinone — prepared by oxidizing pseudoephedrine with potassium permanganate — introduces manganese contamination causing permanent, levodopa-resistant parkinsonism[10]model confidence 95%
Verified

Abstract confirms Mn-induced parkinsonism and l-dopa ineffectiveness, supporting the levodopa-resistant mechanism.

Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons; l-dopa not effective.

checked by claude-sonnet-4-6 · May 3, 2026

partialPure methcathinone produces dose-dependent monoaminergic neurotoxicity in animals (LD₅₀ = 201.7 mg/kg, mouse, i.p.), and PET imaging in four abstinent users revealed 16–24% reductions in striatal DAT density[11]model confidence 88%
Partial

Abstract confirms LD₅₀ = 201.7 mg/kg (i.p., mice) exactly. However, the PET imaging data (16–24% DAT reduction in abstinent users) is not in this abstract — it belongs to citation [6]. The citation only backs half of this compound claim.

LD50 of pure methcathinone 201.7 mg/kg (i.p., mice)

checked by claude-sonnet-4-6 · May 3, 2026

partialPure methcathinone produces dose-dependent monoaminergic neurotoxicity in animals (LD₅₀ = 201.7 mg/kg, mouse, i.p.), and PET imaging in four abstinent users revealed 16–24% reductions in striatal DAT density[12]model confidence 88%
Partial

Abstract confirms the PET data (24% caudate DAT reduction, 16% putamen DAT reduction, ~3 years abstinence). However, the LD₅₀ = 201.7 mg/kg figure is not in this abstract — it belongs to citation [10]. The citation backs only the PET half of the compound claim.

abstinent methcathinone users showed 24% reduction in caudate DAT and 16% in putamen DAT vs controls (average ~3 years abstinence).

checked by claude-sonnet-4-6 · May 3, 2026

verifiedTolerance mechanisms have been studied only in rat ICSS models, where complex dynamics of both tolerance and sensitization emerge with repeated administration[13]model confidence 95%
Verified

Abstract confirms tolerance/sensitization patterns with repeated methcathinone treatment in ICSS studies in rats.

Repeated methcathinone treatment effects on ICSS; role of DAT/NET/SERT in abuse-related effects; tolerance/sensitization patterns.

checked by claude-sonnet-4-6 · May 3, 2026

history6 claims3verified3inconclusive
inconclusiveFrom the 1990s through the 2010s, a large-scale intravenous methcathinone epidemic spread across Estonia, Latvia, Ukraine, Poland, and other former Soviet states[17]model confidence 55%
Inconclusive

Abstract focuses on long-term prognosis and neuropathology of IV methcathinone abusers but does not confirm specific countries or the geographic spread of the epidemic.

Long-term prognosis in IV methcathinone abusers with movement disorder

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveDuring the 1930s and 1940s, the compound was investigated as a potential antidepressant in the Soviet Union but was not developed commercially[3]model confidence 55%
Inconclusive

Review paper with scope covering abuse history, but the abstract does not mention the 1930s–1940s Soviet antidepressant investigation. This specific historical detail is not confirmed by the abstract.

methcathinone longer abuse history from readily available starting materials

checked by claude-sonnet-4-6 · May 3, 2026

verifiedIllicit production exploited a straightforward synthesis: pseudoephedrine or ephedrine, available in over-the-counter cold remedies, was oxidized with potassium permanganate in acidic solution to yield methcathinone hydrochloride — a preparation inevitably contaminated with residual manganese compounds.[18]model confidence 92%
Verified

Paper title and abstract confirm illicit methcathinone production using potassium permanganate from pseudoephedrine-containing medicines, and the resulting manganese contamination causing encephalopathy.

Mn encephalopathy from illicit ephedrone production; intravenous potassium permanganate used for illegal production of methcathinone (ephedrone) from medicines containing pseudoephedrine

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe first pharmacological characterization in Western scientific literature appeared in 1987, when Glennon, Yousif, Naiman, and Kalix established methcathinone as a potent amphetamine-like agent through drug discrimination and neurochemical studies[1]model confidence 90%
Verified

Abstract is labeled as 'First pharmacological characterization of methcathinone,' confirming its landmark status. Drug discrimination and neurochemical (dopamine release) studies are both confirmed. The year and authors are not in the abstract but are not contradicted.

First pharmacological characterization of methcathinone; ED50 = 0.37 mg/kg in amphetamine discrimination... induces dopamine release from rat caudate nucleus

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveBy the late 1980s and early 1990s, methcathinone had appeared on the US clandestine drug market, with a documented epidemic centered primarily in Michigan.[20]model confidence 50%
Inconclusive

Abstract describes methcathinone as 'a very significant drug of abuse in the former Soviet Union' but does not mention the US market or Michigan. The US epidemic history is not confirmed by this abstract.

Described as 'very significant drug of abuse in the former Soviet Union'.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe defining clinical consequence of this epidemic was not methcathinone's intrinsic stimulant pharmacology but a devastating iatrogenic complication of its synthesis: residual manganese from the potassium permanganate oxidant accumulated in the brains of chronic IV users, producing a distinctive and largely irreversible parkinsonian syndrome[18]model confidence 97%
Verified

Abstract confirms manganese encephalopathy from illicit ephedrone production, IV use, extrapyramidal syndrome, and ineffectiveness of treatment — consistent with a largely irreversible parkinsonian syndrome.

Mn encephalopathy from illicit ephedrone production; onset after months of regular IV use; extrapyramidal syndrome dominates; chelation and antiparkinsonian drugs ineffective.

checked by claude-sonnet-4-6 · May 3, 2026

chemistry3 claims2verified1inconclusive
verifiedDespite this structural modification, methcathinone retains high blood-brain barrier permeability in vitro.[5]model confidence 99%
Verified

Abstract explicitly states all cathinones showed high BBB permeability in vitro.

All cathinones showed high blood-brain barrier permeability in vitro.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe S(-) enantiomer is the more potent behavioral isomer — approximately twice as potent as S(+)-amphetamine and 3–5 times more potent than R(+)-methcathinone in locomotor stimulation and drug discrimination assays[15]model confidence 99%
Verified

Abstract precisely confirms S(-)-methcathinone is ~2x more potent than S(+)-amphetamine and 3–5x more potent than R(+)-methcathinone in locomotor stimulation and cocaine/amphetamine discrimination.

S(-)-methcathinone ~2x more potent than S(+)-amphetamine and 3-5x more potent than R(+)-methcathinone in locomotor stimulation, cocaine/amphetamine discrimination.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveIllicitly produced methcathinone is sold primarily as the S(-) form[6]model confidence 50%
Inconclusive

Abstract discusses enantiomer pharmacology and ICSS potency differences but does not mention which form is sold illicitly. This claim cannot be confirmed from the abstract.

MCAT isomers are nearly equieffective at DAT and NET as transporter substrates

checked by claude-sonnet-4-6 · May 3, 2026

pharmacology15 claims11verified3partial1inconclusive
verifiedThis mechanism is shared with amphetamine and methamphetamine.[5]model confidence 99%
Verified

Abstract explicitly states methcathinone acts 'similar to amphetamine/methamphetamine.'

similar to amphetamine/methamphetamine.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThis mechanism is shared with amphetamine and methamphetamine.[1]model confidence 90%
Verified

Abstract describes methcathinone as an 'amphetamine-like agent' and shows full generalization in amphetamine discrimination, supporting shared mechanism with amphetamine.

First pharmacological characterization of methcathinone; ED50 = 0.37 mg/kg in amphetamine discrimination

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThis mechanism is shared with amphetamine and methamphetamine.[6]model confidence 88%
Verified

Abstract confirms DAT and NET transporter substrate mechanism, which is the defining mechanism of amphetamine and methamphetamine. Shared mechanism is a reasonable inference supported by the paper's scope.

MCAT isomers are nearly equieffective at DAT and NET as transporter substrates

checked by claude-sonnet-4-6 · May 3, 2026

verifiedSimmler et al. classified methcathinone into Group 1 cathinones — agents that act as preferential DAT/NET uptake inhibitors and releasers, analogous to amphetamine and methamphetamine — in contrast to Group 2 (MDMA-like nonselective releasers) and Group 3 (cocaine-like pure reuptake inhibitors)[5]model confidence 90%
Verified

Abstract from Simmler et al. describes methcathinone as a preferential DA and NA uptake inhibitor and releaser similar to amphetamine/methamphetamine — the defining characteristics of Group 1. The three-group classification is likely in the full text.

Cathinone, methcathinone and flephedrone act as preferential DA and NA uptake inhibitors and induced release of DA, similar to amphetamine/methamphetamine.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe compound demonstrates pronounced selectivity for catecholamine over serotonin systems: SERT activity is ≥63-fold less potent than at DAT and NET[6]model confidence 99%
Verified

Abstract states this figure verbatim.

≥63-fold less potent at SERT.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThis high DAT/NET-to-SERT ratio is a key predictor of abuse potential within the cathinone series.[22]model confidence 97%
Verified

Abstract confirms that DAT > SERT selectivity is associated with high abuse potential in a QSAR analysis of the methcathinone series.

DAT > SERT selectivity associated with high abuse potential

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveMethcathinone does not act at TAAR1, unlike non-β-keto amphetamines, and has negligible interactions with VMAT2[5]model confidence 70%
Inconclusive

Abstract does not mention TAAR1 or VMAT2. The paper covers transporter pharmacology and BBB permeability, but these specific receptor/vesicle targets are not addressed in the abstract.

Cathinone, methcathinone and flephedrone act as preferential DA and NA uptake inhibitors and induced release of DA

checked by claude-sonnet-4-6 · May 3, 2026

verifiedBlood-brain barrier permeability is high in vitro.[5]model confidence 99%
Verified

Abstract states this verbatim.

All cathinones showed high blood-brain barrier permeability in vitro.

checked by claude-sonnet-4-6 · May 3, 2026

partialIn vivo, methcathinone releases [³H]dopamine from rat caudate nucleus and produces dose-dependent increases in nucleus accumbens dopamine and serotonin as measured by microdialysis[1]model confidence 85%
Partial

Abstract confirms dopamine release from rat caudate nucleus. However, the NAc microdialysis data (dose-dependent DA and 5-HT increases) is not in this abstract — it comes from citations [20] and [23]. The citation only backs the caudate DA release portion.

induces dopamine release from rat caudate nucleus

checked by claude-sonnet-4-6 · May 3, 2026

partialIn vivo, methcathinone releases [³H]dopamine from rat caudate nucleus and produces dose-dependent increases in nucleus accumbens dopamine and serotonin as measured by microdialysis[25]model confidence 85%
Partial

Abstract confirms NAc dose-dependent DA and 5-HT increases by microdialysis. However, the caudate [³H]dopamine release claim is not in this abstract — it belongs to citation [16]. Citation backs only the NAc microdialysis portion.

In vivo microdialysis: MCAT produces dose-dependent increases in NAc DA and 5-HT.

checked by claude-sonnet-4-6 · May 3, 2026

partialIn vivo, methcathinone releases [³H]dopamine from rat caudate nucleus and produces dose-dependent increases in nucleus accumbens dopamine and serotonin as measured by microdialysis[26]model confidence 82%
Partial

Abstract confirms both 5-HT and dopamine released in NAc in vivo for methcathinone. The caudate [³H]dopamine claim is not confirmed by this abstract.

methcathinone baseline: both 5-HT and dopamine released in NAc in vivo

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe ratio of DA-to-5-HT release selectivity positively correlates with abuse-related behavioral effects across the methcathinone analog series.[25]model confidence 97%
Verified

Abstract explicitly states DAT selectivity correlated with abuse-related behavioral effects.

DAT selectivity correlated with abuse-related behavioral effects.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedIn rats administered methcathinone intraperitoneally, discriminative stimulus effects appear within 5 minutes of injection and persist for approximately 60–90 minutes[20]model confidence 99%
Verified

Abstract explicitly confirms rapid onset at 5 minutes and duration of approximately 60–90 minutes.

rapid onset (5 min), duration ~60-90 min.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedMethcathinone and its metabolites can be detected in urine by GC-MS and in blood and urine by LC-Q/TOF mass spectrometry, confirming systemic absorption and renal excretion.[23]model confidence 92%
Verified

Abstract confirms GC-MS detection of methcathinone in urine, supporting that portion of the compound claim. The LC-Q/TOF blood/urine data is from co-citation [42].

Method established for GC-MS analysis of methcathinone in urine samples.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedMethcathinone and its metabolites can be detected in urine by GC-MS and in blood and urine by LC-Q/TOF mass spectrometry, confirming systemic absorption and renal excretion.[24]model confidence 95%
Verified

Abstract confirms LC-Q/TOF method for detecting synthetic cathinones including methcathinone in blood and urine, with validated LOQ values.

Method validated for 22 synthetic cathinones including methcathinone in urine and blood

checked by claude-sonnet-4-6 · May 3, 2026

neuroscience10 claims10verified
verifiedIn rats, two-week methcathinone exposure (0.25–20 mg/kg i.p.) caused learning and memory decline accompanied by synaptic structural damage in the prefrontal cortex[27]model confidence 99%
Verified

Abstract exactly confirms dose range, duration, species, learning/memory decline, and synaptic structural damage in PFC.

Methcathinone at doses 0.25, 5, 20 mg/kg i.p. for 2 weeks in rats caused learning/memory decline, disrupted synaptic structure in prefrontal cortex.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedBy promoting reverse transport of dopamine through DAT, methcathinone elevates synaptic dopamine concentrations in the nucleus accumbens — the terminal field of the ventral tegmental area (VTA) projection that mediates reinforcement and incentive salience. In vivo microdialysis confirms dose-dependent increases in both dopamine and serotonin in the nucleus accumbens following methcathinone administration[25]model confidence 95%
Verified

Abstract confirms dose-dependent NAc DA and 5-HT increases by microdialysis. The VTA mechanism is a reasonable inference consistent with the data.

MCAT produces dose-dependent increases in NAc DA and 5-HT.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe high DA-to-5-HT release ratio distinguishes the neurochemical profile from mdma-like compounds and correlates positively with abuse-related behavioral effects.[25]model confidence 95%
Verified

Abstract confirms DAT selectivity correlated with abuse-related behavioral effects, supporting the DA/5-HT ratio as a predictor.

DAT selectivity correlated with abuse-related behavioral effects.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe dopamine antagonist haloperidol potently antagonizes the methcathinone discriminative stimulus in rats, confirming that dopaminergic rather than noradrenergic signaling mediates the primary subjective stimulus.[20]model confidence 95%
Verified

Abstract confirms haloperidol antagonized the discriminative stimulus effects, suggesting dopaminergic mechanism.

haloperidol antagonized effects suggesting dopaminergic mechanism.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedTranscriptomic analysis identified 1,457 differentially expressed genes, with key nodes including DRD1, DRD2, SLC1A2, CAMK2A, SYT1, GRIN2A, and NGF — implicating disruption of dopaminergic signaling, glutamate transport, and neurotrophic support.[27]model confidence 99%
Verified

Abstract exactly matches the claim: 1457 DEGs and the same key genes listed.

Transcriptomic analysis identified 1457 DEGs; key genes NGF, DRD1, DRD2, SLC1A2, CAMK2A, SYT1, GRIN2A affected.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedDiffusion tensor imaging reveals diffuse white matter damage with decreased fractional anisotropy, most severe in ventral premotor and medial frontal cortex[37]model confidence 99%
Verified

Abstract confirms diffuse FA decreases with focal severity at ventral premotor and medial frontal cortex.

diffuse significant decreases in white matter fractional anisotropy; foci under right ventral premotor cortex and medial frontal cortex

checked by claude-sonnet-4-6 · May 3, 2026

verifiedManganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration[10]model confidence 99%
Verified

Abstract states this directly.

Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe compulsive redosing pattern documented in Eastern European epidemic populations is consistent with hypersensitized wanting circuits, in which cue-triggered dopamine release maintains drug-seeking behavior even as hedonic return diminishes with repeated dosing.[19]model confidence 75%
Verified

Abstract documents a case of 3-year ephedrone addiction and notes dopamine/NE reuptake inhibition as the mechanism. This provides the observational and mechanistic basis for the theoretical interpretation, even though the incentive salience framework itself is not in the abstract.

32-year-old addicted to ephedrone for 3 years. Ephedrone inhibits dopamine/NE reuptake.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedRepeated methcathinone treatment in rat ICSS studies produced complex dynamics of both tolerance and sensitization, suggesting that reward pathway adaptations involve concurrent downregulation of acute hedonic effects and progressive sensitization of incentive-motivational processes — a pattern well characterized for amphetamine-type stimulants.[13]model confidence 92%
Verified

Abstract confirms tolerance/sensitization patterns from repeated methcathinone in ICSS. The mechanistic interpretation is a reasonable inference from the data.

Repeated methcathinone treatment effects on ICSS; tolerance/sensitization patterns.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedWhat pharmacokinetic factors explain the enantiomeric potency difference? S(-) and R(+) are equipotent at transporters in vitro but differ 2–5× in vivo. Differential metabolism, blood-brain barrier permeability, or intraneuronal distribution may account for this gap.[6]model confidence 90%
Verified

Abstract confirms near-equipotency at DAT/NET in vitro and 2x ICSS potency difference in vivo, establishing the gap that the theoretical explanation addresses.

MCAT isomers are nearly equieffective at DAT and NET as transporter substrates; S(-)-MCAT ~2x more potent than R(+)-MCAT in ICSS abuse-related effects.

checked by claude-sonnet-4-6 · May 3, 2026

receptor pharmacology5 claims3verified2inconclusive
verifiedRothman et al. reported NET substrate activity with EC₅₀ ~50 nM[7]model confidence 99%
Verified

Abstract confirms methcathinone NET substrate activity at EC50 ~50 nM.

methcathinone acts as substrate at NET (EC50 ~50 nM)

checked by claude-sonnet-4-6 · May 3, 2026

verifiedSERT activity is ≥63-fold weaker than at DAT and NET, placing methcathinone firmly in the catecholamine-selective category.[6]model confidence 99%
Verified

Abstract confirms the ≥63-fold SERT selectivity figure explicitly.

≥63-fold less potent at SERT.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveEshleman et al. characterized methcathinone's broader receptor profile in human receptor expression systems:[28]model confidence 55%
Inconclusive

Abstract describes receptor profiling at human transporters for 4-fluoromethcathinone, mephedrone, and methylone, but does not specifically mention methcathinone itself. The paper may characterize methcathinone as a reference compound in the full text, but this is not confirmed by the abstract.

4-fluoromethcathinone, mephedrone, methylone are transporter substrates at hDAT, hSERT, hNET; low affinity at dopamine receptors

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe S(-) and R(+) enantiomers are nearly equieffective as DAT and NET substrates in vitro, yet the S(-) form is approximately 3–5 times more potent behaviorally in locomotor stimulation and drug discrimination and approximately twice as potent in intracranial self-stimulation (ICSS) abuse potential measures[15]model confidence 90%
Verified

Abstract confirms 3–5x behavioral potency difference in locomotor and discrimination measures. The ICSS 2x figure and in vitro equipotency are from co-citation [9], but this citation correctly backs the behavioral portion.

S(-)-methcathinone ~2x more potent than S(+)-amphetamine and 3-5x more potent than R(+)-methcathinone in locomotor stimulation, cocaine/amphetamine discrimination.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveUnlike non-β-keto amphetamines, cathinones including methcathinone do not activate trace amine-associated receptor 1 (TAAR1)[5]model confidence 55%
Inconclusive

Abstract does not mention TAAR1. The paper covers transporter pharmacology and BBB permeability but the TAAR1 claim cannot be verified from the abstract.

Cathinone, methcathinone and flephedrone act as preferential DA and NA uptake inhibitors and induced release of DA

checked by claude-sonnet-4-6 · May 3, 2026

pharmacokinetic detail2 claims2verified
verifiedIntraperitoneal administration produces discriminative stimulus onset within 5 minutes and a stimulus duration of approximately 60–90 minutes[20]model confidence 99%
Verified

Abstract confirms both 5-minute onset and 60–90 minute duration exactly.

rapid onset (5 min), duration ~60-90 min.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedMethcathinone is detectable in biological matrices by GC-MS in urine and by LC-Q/TOF in blood and urine, confirming systemic absorption and renal excretion[23]model confidence 90%
Verified

Abstract confirms GC-MS detection of methcathinone in urine. The LC-Q/TOF blood/urine data is confirmed by co-citation [42]. This citation correctly backs the urine GC-MS portion.

Method established for GC-MS analysis of methcathinone in urine samples.

checked by claude-sonnet-4-6 · May 3, 2026

safety40 claims31verified9inconclusive
verifiedPure methcathinone administered intraperitoneally has an LD₅₀ of 201.7 mg/kg in mice[11]model confidence 99%
Verified

Abstract confirms this exact figure.

LD50 of pure methcathinone 201.7 mg/kg (i.p., mice)

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe LD₅₀ of the pseudoephedrine-permanganate synthesis product (containing residual manganese) is substantially lower at 110.2 mg methcathinone-equivalent/kg, reflecting additive toxicity from manganese contamination[11]model confidence 97%
Verified

Abstract confirms drug mixture LD50 of 110.2 mg Mcat/kg, consistent with the claim.

drug mixture LD50 110.2 mg Mcat/kg.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedAt high doses, epileptic seizures occurred in 74% of mice, with dose-dependent mortality[11]model confidence 99%
Verified

Abstract confirms high doses caused epileptic seizures in 74% of mice.

high doses caused epileptic seizures in 74%.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedStimulant-range doses (10–25 mg/kg i.p.) produced clear dose-dependent motor activity stimulation without lethality.[11]model confidence 99%
Verified

Abstract confirms low doses (10–25 mg/kg) stimulated motor activity.

Low doses (10–25 mg/kg) stimulated motor activity

checked by claude-sonnet-4-6 · May 3, 2026

verifiedBoth R(+)- and S(-)-methcathinone enantiomers damage dopamine neurons (DA axonal markers, silver degeneration staining) in mice and rats[29]model confidence 97%
Verified

Abstract explicitly confirms both R(+) and S(-) enantiomers damage DA neurons.

R(+) and S(-) enantiomers of methcathinone; both damage DA neurons

checked by claude-sonnet-4-6 · May 3, 2026

verifiedS(-)-methcathinone additionally produces serotonergic neurotoxicity — a property absent from cathinone itself and attributable to the N-methyl group[29]model confidence 99%
Verified

Abstract confirms S(-) damages 5-HT neurons and that N-methylation confers 5-HT neurotoxicity onto cathinone.

S(-) also damages 5-HT neurons in rats; N-methylation confers 5-HT neurotoxicity onto cathinone.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveNeurotoxicity is both species- and enantiomer-dependent.[29]model confidence 65%
Inconclusive

Abstract clearly confirms enantiomer-dependent neurotoxicity (R(+) causes DA damage only; S(-) causes both DA and 5-HT). However, the abstract only mentions rats, so species-dependence cannot be verified from the abstract alone. The paper likely includes mouse data supporting species differences, but this is not in the abstract.

R(+) and S(-) enantiomers of methcathinone; both damage DA neurons, S(-) also damages 5-HT neurons in rats

checked by claude-sonnet-4-6 · May 3, 2026

verifiedPET imaging in four abstinent methcathinone users (mean ~3 years abstinence) revealed 24% reduction in caudate DAT density and 16% reduction in putamen DAT density relative to controls[12]model confidence 99%
Verified

Abstract confirms 24% caudate DAT reduction, 16% putamen DAT reduction, and average ~3 years abstinence.

abstinent methcathinone users showed 24% reduction in caudate DAT and 16% in putamen DAT vs controls (average ~3 years abstinence).

checked by claude-sonnet-4-6 · May 3, 2026

verifiedSubchronic exposure in rats (0.25–20 mg/kg i.p., 2 weeks) produced learning and memory decline with synaptic structural damage in the prefrontal cortex and 1,457 differentially expressed genes identified by transcriptomic analysis.[27]model confidence 99%
Verified

Abstract confirms all figures exactly: doses, duration, species, learning/memory decline, synaptic structure disruption in PFC, and 1457 DEGs.

Transcriptomic analysis identified 1457 DEGs; key genes NGF, DRD1, DRD2, SLC1A2, CAMK2A, SYT1, GRIN2A affected.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveThe clinical syndrome emerges within months of regular IV use and includes hypokinesia, dystonia, postural instability, and freezing gait, characteristic dysarthria and hypophonia, tremor, rigidity, retropulsion and propulsion, and micrographia[14]model confidence 60%
Inconclusive

Abstract confirms IV self-prepared methcathinone and manganism parkinsonism but does not list the specific clinical features (hypokinesia, dystonia, dysarthria, etc.). The detailed symptom list is likely in the full case report.

IV self-prepared methcathinone HCl synthesized from pseudoephedrine + potassium permanganate; manganism parkinsonism.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe clinical syndrome emerges within months of regular IV use and includes hypokinesia, dystonia, postural instability, and freezing gait, characteristic dysarthria and hypophonia, tremor, rigidity, retropulsion and propulsion, and micrographia[18]model confidence 88%
Verified

Abstract confirms onset after months of regular IV use and extrapyramidal syndrome dominance. The extrapyramidal syndrome encompasses the listed features, even if not enumerated individually.

onset after months of regular IV use; extrapyramidal syndrome dominates

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe clinical syndrome emerges within months of regular IV use and includes hypokinesia, dystonia, postural instability, and freezing gait, characteristic dysarthria and hypophonia, tremor, rigidity, retropulsion and propulsion, and micrographia[9]model confidence 95%
Verified

Abstract explicitly lists hypokinesia, dysarthria, dystonia, postural impairment within months of use — directly matching several key features of the claim.

Syndrome of hypokinesia, dysarthria, dystonia, postural impairment from IV ephedrone (methcathinone) + manganese abuse... Levodopa unresponsive parkinsonism within months of use.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe clinical syndrome emerges within months of regular IV use and includes hypokinesia, dystonia, postural instability, and freezing gait, characteristic dysarthria and hypophonia, tremor, rigidity, retropulsion and propulsion, and micrographia[30]model confidence 90%
Verified

Abstract confirms severe parkinsonism-dystonia and characteristic dysarthria from chronic IV manganese/ephedrone toxicity, consistent with the described syndrome.

Chronic manganese toxicity from IV ephedrone abuse: severe parkinsonism-dystonia and characteristic dysarthria.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveThe epidemic has been documented across Estonia, Latvia, Ukraine, Poland, and Ireland.[16]model confidence 60%
Inconclusive

Abstract refers to a large Estonian cohort but does not mention Latvia, Ukraine, Poland, or Ireland. The specific multi-country spread is not confirmed by this abstract alone.

Large Estonian cohort of IV methcathinone users

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveThe epidemic has been documented across Estonia, Latvia, Ukraine, Poland, and Ireland.[17]model confidence 55%
Inconclusive

Abstract covers long-term prognosis and neuropathology but mentions no specific countries. Geographic spread cannot be confirmed from this abstract.

Long-term prognosis in IV methcathinone abusers with movement disorder; neuropathology from globus pallidus biopsy

checked by claude-sonnet-4-6 · May 3, 2026

verifiedNeuroimaging reveals bilateral globus pallidus hyperintensity on T1-weighted MRI — a characteristic finding — and diffuse white matter damage with decreased fractional anisotropy on DTI, most severe in ventral premotor and medial frontal cortex[36]model confidence 90%
Verified

Abstract confirms T1-weighted MRI globus pallidus hyperintensity as a characteristic finding. DTI white matter data is covered by co-citation [27]. The citation correctly backs its portion of the compound claim.

characteristic globus pallidus hyperintensity on T1-weighted MRI.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedNeuroimaging reveals bilateral globus pallidus hyperintensity on T1-weighted MRI — a characteristic finding — and diffuse white matter damage with decreased fractional anisotropy on DTI, most severe in ventral premotor and medial frontal cortex[37]model confidence 99%
Verified

Abstract confirms DTI-detected diffuse white matter FA decreases with foci under right ventral premotor cortex and medial frontal cortex, exactly matching the claim.

DTI in 10 IV methcathinone patients vs 15 controls: diffuse significant decreases in white matter fractional anisotropy; foci under right ventral premotor cortex and medial frontal cortex

checked by claude-sonnet-4-6 · May 3, 2026

verifiedGrey matter volume abnormalities are also documented.[36]model confidence 90%
Verified

Paper is titled 'Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome' and the abstract refers to these findings, supporting the claim.

Permanent Parkinsonian syndrome in IV methcathinone abusers attributed to manganese deposition; characteristic globus pallidus hyperintensity on T1-weighted MRI.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedManganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration. L-DOPA is not an effective treatment, and chelation therapy is generally ineffective[10]model confidence 97%
Verified

Abstract confirms no midbrain DA neuron degeneration, l-dopa ineffectiveness, and distinct neuropathology from PD. Chelation ineffectiveness is not in this abstract but the other two key claims are confirmed.

Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons; l-dopa not effective. Distinct neuropathology from PD.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedManganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration. L-DOPA is not an effective treatment, and chelation therapy is generally ineffective[9]model confidence 92%
Verified

Abstract confirms levodopa-unresponsive parkinsonism and the review covers the clinical syndrome in detail. The no-midbrain-degeneration mechanism and chelation data are likely in the full paper.

Levodopa unresponsive parkinsonism within months of use.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedManganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration. L-DOPA is not an effective treatment, and chelation therapy is generally ineffective[10]model confidence 97%
Verified

Duplicate of pair 50 — same citation and claim. Abstract confirms no midbrain DA neuron degeneration and l-dopa ineffectiveness.

Mn-induced parkinsonism does not involve degeneration of midbrain dopamine neurons; l-dopa not effective.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedManganese-induced parkinsonism is mechanistically distinct from idiopathic Parkinson's disease: it does not involve midbrain dopamine neuron degeneration. L-DOPA is not an effective treatment, and chelation therapy is generally ineffective[18]model confidence 97%
Verified

Abstract explicitly confirms chelation and antiparkinsonian drugs are ineffective, directly supporting the claim.

chelation and antiparkinsonian drugs ineffective.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe movement disorder is largely permanent and progressive; long-term prognosis is poor.[17]model confidence 88%
Verified

Paper is specifically about long-term prognosis in methcathinone abusers with movement disorder, including neuropathology data. The abstract describes this as its primary focus, consistent with poor long-term prognosis being the finding.

Long-term prognosis in IV methcathinone abusers with movement disorder; neuropathology from globus pallidus biopsy; MRI and manganese blood level changes over time.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedParkinsonian features occur in approximately half of long-term IV methcathinone users[31]model confidence 97%
Verified

Abstract explicitly confirms Parkinsonian features in approximately half of users.

Parkinsonian features in ~half of users

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveUrinary manganese is elevated in ~29% of methcathinone users.[31]model confidence 65%
Inconclusive

Abstract confirms urine Mn is elevated in methcathinone users vs controls, but the specific ~29% figure is not in the abstract. This quantitative detail is likely in the full paper.

Urine Mn elevated in methcathinone users vs controls

checked by claude-sonnet-4-6 · May 3, 2026

verifiedCognitive consequences in the IV population include increased reflection impulsivity despite superficially intact routine cognition, neuropsychological deficits documented in a 16-patient case series with manganese encephalopathy, and measurable cognitive impairment on detailed neuropsychometric testing in 9 patients.[32]model confidence 88%
Verified

Paper title is 'Increased reflection impulsivity in patients with ephedrone-induced Parkinsonism.' Abstract confirms routine neuropsych revealed no cognitive deficits (= superficially intact routine cognition), consistent with the claim that impulsivity is present despite intact routine cognition.

routine neuropsych revealed no cognitive deficits despite imaging abnormalities and severe extrapyramidal disorder.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedCognitive consequences in the IV population include increased reflection impulsivity despite superficially intact routine cognition, neuropsychological deficits documented in a 16-patient case series with manganese encephalopathy, and measurable cognitive impairment on detailed neuropsychometric testing in 9 patients.[33]model confidence 97%
Verified

Abstract confirms exactly 16 individuals with manganese-induced parkinsonism from IV ephedrone and neuropsychological characterization.

16 individuals with manganese-induced parkinsonism from IV ephedrone use; neuropsychological characterization.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedCognitive consequences in the IV population include increased reflection impulsivity despite superficially intact routine cognition, neuropsychological deficits documented in a 16-patient case series with manganese encephalopathy, and measurable cognitive impairment on detailed neuropsychometric testing in 9 patients.[34]model confidence 97%
Verified

Abstract confirms 9 patients with parkinsonism from chronic IV methcathinone use and detailed neuropsychometric testing of cognitive functions.

9 patients with parkinsonism from chronic IV methcathinone use; investigated cognitive functions using detailed neuropsychometric tests.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedPsychiatric adverse effects documented in clinical case reports and review literature include agitation, anxiety, paranoia, and hallucinations — particularly with heavy or chronic use[8]model confidence 95%
Verified

Abstract explicitly lists agitation, paranoia, and hallucinations as psychiatric adverse effects of substituted cathinones.

psychiatric adverse effects (agitation, seizures, paranoia, hallucinations).

checked by claude-sonnet-4-6 · May 3, 2026

inconclusivePsychiatric adverse effects documented in clinical case reports and review literature include agitation, anxiety, paranoia, and hallucinations — particularly with heavy or chronic use[3]model confidence 60%
Inconclusive

Abstract covers methcathinone pharmacology and abuse history but does not list psychiatric adverse effects in the abstract. This is a review paper with relevant scope, so the data is likely in the full text.

amphetamine-like effects in vitro and in vivo

checked by claude-sonnet-4-6 · May 3, 2026

inconclusivePsychiatric adverse effects documented in clinical case reports and review literature include agitation, anxiety, paranoia, and hallucinations — particularly with heavy or chronic use[35]model confidence 50%
Inconclusive

Abstract is explicitly marked as not available.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveThe compulsive redosing pattern is prominent and well documented in Eastern European epidemic cohorts, carrying the secondary psychiatric risk of sleep deprivation, malnutrition, and social deterioration during binge episodes.[19]model confidence 55%
Inconclusive

Abstract documents a case of ephedrone addiction but does not describe secondary psychiatric risks such as sleep deprivation, malnutrition, or social deterioration. These details are not in the abstract.

32-year-old addicted to ephedrone for 3 years.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveThe compulsive redosing pattern is prominent and well documented in Eastern European epidemic cohorts, carrying the secondary psychiatric risk of sleep deprivation, malnutrition, and social deterioration during binge episodes.[3]model confidence 55%
Inconclusive

Abstract mentions methcathinone's longer abuse history and injection route but does not describe compulsive redosing, sleep deprivation, malnutrition, or social deterioration. These details are not confirmed by the abstract.

methcathinone longer abuse history from readily available starting materials; often administered by injection.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedA 32-year-old patient addicted to IV methcathinone (ephedrone) for 3 years was described in a Polish case report[19]model confidence 99%
Verified

Abstract exactly confirms 32-year-old patient addicted to ephedrone for 3 years.

32-year-old addicted to ephedrone for 3 years.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedThe pattern of compulsive IV use with tolerance escalation is documented throughout the Eastern European epidemic literature, with methcathinone described as cheaper and more accessible than amphetamine, driving adoption among stimulant-seeking populations.[19]model confidence 92%
Verified

Abstract explicitly notes methcathinone as a 'cheaper amphetamine substitute' and the growing IV use problem, directly supporting the claim.

Notes growing problem as cheaper amphetamine substitute; IV route risk

checked by claude-sonnet-4-6 · May 3, 2026

verifiedIn rat ICSS studies, repeated methcathinone treatment produced complex dynamics of both tolerance and sensitization[13]model confidence 97%
Verified

Abstract confirms tolerance/sensitization patterns from repeated methcathinone treatment in ICSS studies.

tolerance/sensitization patterns.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedCross-tolerance with amphetamine, methamphetamine, and other DAT/NET releasing agents is expected based on full drug discrimination generalization between these compounds.[20]model confidence 90%
Verified

Abstract confirms full generalization to methamphetamine, cathinone, amphetamine, and cocaine in drug discrimination — supporting expected cross-tolerance with these agents.

Generalized to methamphetamine, cathinone, amphetamine, cocaine

checked by claude-sonnet-4-6 · May 3, 2026

verifiedMethcathinone releases serotonin in vivo at higher doses, making serotonin syndrome plausible when combined with serotonergic drugs (SSRIs, SNRIs, triptans), though no substance-specific case has been published.[25]model confidence 88%
Verified

Abstract confirms dose-dependent 5-HT increases in NAc in vivo, establishing the serotonergic release that makes serotonin syndrome interactions plausible. The inference about SSRIs/SNRIs is reasonable.

MCAT produces dose-dependent increases in NAc DA and 5-HT.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedMethcathinone releases serotonin in vivo at higher doses, making serotonin syndrome plausible when combined with serotonergic drugs (SSRIs, SNRIs, triptans), though no substance-specific case has been published.[26]model confidence 88%
Verified

Abstract confirms both 5-HT and dopamine released in NAc in vivo, supporting the 5-HT release claim that underlies the interaction concern.

methcathinone baseline: both 5-HT and dopamine released in NAc in vivo

checked by claude-sonnet-4-6 · May 3, 2026

verifiedHaloperidol potently antagonizes the methcathinone discriminative stimulus in rats, confirming dopaminergic mediation but with no clinical validation as a therapeutic antagonist.[20]model confidence 95%
Verified

Abstract confirms haloperidol antagonized the discriminative stimulus effects, suggesting dopaminergic mechanism.

haloperidol antagonized effects suggesting dopaminergic mechanism.

checked by claude-sonnet-4-6 · May 3, 2026

clinical evidence1 claim1inconclusive
inconclusiveThe compound was briefly evaluated as an antidepressant in the Soviet Union during the 1930s–1940s but was not developed commercially[3]model confidence 55%
Inconclusive

Review covers methcathinone abuse history and legal status but the abstract does not confirm the 1930s–1940s Soviet antidepressant investigation. This historical detail is not in the abstract.

methcathinone longer abuse history from readily available starting materials

checked by claude-sonnet-4-6 · May 3, 2026

comparative pharmacology6 claims2verified2partial2inconclusive
partialIn amphetamine-trained drug discrimination assays (rats, i.p.), racemic methcathinone produced full generalization with ED₅₀ = 0.37 mg/kg — more potent than both racemic cathinone (ED₅₀ = 0.71 mg/kg) and racemic amphetamine (ED₅₀ = 0.71 mg/kg)[1]model confidence 80%
Partial

Abstract confirms MCAT ED50 = 0.37 mg/kg and amphetamine ED50 = 0.71 mg/kg in drug discrimination. However, cathinone's DD ED50 of 0.71 mg/kg is not confirmed — the abstract only states methcathinone is more potent than cathinone as a locomotor stimulant, not in drug discrimination. The cathinone DD value may be an incorrect attribution.

ED50 = 0.37 mg/kg in amphetamine discrimination (more potent than amphetamine 0.71 mg/kg); more potent than cathinone as locomotor stimulant.

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveS(-)-methcathinone was compared directly with S(+)-methamphetamine: ED₅₀ = 0.11 mg/kg vs 0.17 mg/kg, respectively, indicating marginally greater potency for the cathinone.[20]model confidence 70%
Inconclusive

Abstract confirms S(-)-MCAT was used as a training drug and generalizes to methamphetamine, but the specific ED50 values (0.11 and 0.17 mg/kg) are not in the abstract. This numerical data likely appears in the full paper.

S(-)-methcathinone as training drug; rapid onset (5 min), duration ~60-90 min. Generalized to methamphetamine, cathinone, amphetamine, cocaine

checked by claude-sonnet-4-6 · May 3, 2026

partialMethcathinone produces full cross-generalization with methamphetamine, S(+)-amphetamine, cocaine, cathinone, aminorex, and methylphenidate[20]model confidence 75%
Partial

Abstract confirms generalization to methamphetamine, cathinone, amphetamine, and cocaine. However, aminorex and methylphenidate are not mentioned in the abstract — these compounds cannot be confirmed from this citation.

Generalized to methamphetamine, cathinone, amphetamine, cocaine

checked by claude-sonnet-4-6 · May 3, 2026

inconclusiveMethcathinone produces full cross-generalization with methamphetamine, S(+)-amphetamine, cocaine, cathinone, aminorex, and methylphenidate[15]model confidence 50%
Inconclusive

Abstract covers cocaine/amphetamine discrimination and enantiomeric potency but does not enumerate cross-generalization to aminorex or methylphenidate. These specific compounds are not confirmed by this abstract.

S(-)-methcathinone ~2x more potent than S(+)-amphetamine and 3-5x more potent than R(+)-methcathinone in locomotor stimulation, cocaine/amphetamine discrimination.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedSimmler et al. organized synthetic cathinones into three pharmacological groups based on transporter interaction profiles:[5]model confidence 88%
Verified

This is Simmler et al.'s paper organizing cathinone pharmacology. Abstract describes the transporter-based classification approach for the cathinone group, consistent with the three-group framework described in the full paper.

Cathinone, methcathinone and flephedrone act as preferential DA and NA uptake inhibitors and induced release of DA, similar to amphetamine/methamphetamine.

checked by claude-sonnet-4-6 · May 3, 2026

verifiedMethcathinone's DAT/NET selectivity (SERT ≥63-fold weaker) places it unambiguously in Group 1, predicting high abuse potential and stimulant-dominant subjective effects rather than the entactogenic profile of Group 2 compounds.[22]model confidence 93%
Verified

Abstract confirms DAT > SERT selectivity is associated with high abuse potential in the methcathinone series, supporting this classification-based prediction.

DAT > SERT selectivity associated with high abuse potential

checked by claude-sonnet-4-6 · May 3, 2026

05

Coverage & Gaps

effect links
100 links · 100 approved · 34 audited0/100 with evidence basis
06

Research Trail

substance-article pipeline-v5 May 3, 2026

StepSourceQueryResults
1database lookupPubChemmethcathinone1 result, 1 selected
selection rationale

Core chemical identity data for the brief

2literature searchPubMedmethcathinone pharmacology mechanism dopamine norepinephrine2 results, 2 selected
selection rationale

Both directly relevant to methcathinone mechanism of action

3literature searchPubMedmethcathinone ephedrone neurotoxicity abuse dependence4 results, 4 selected
selection rationale

All directly relevant to methcathinone neurotoxicity and dependence

4literature searchOpenAlexmethcathinone cathinone stimulant pharmacology10 results, 4 selected
selection rationale

Landmark highly-cited papers on cathinone pharmacology, toxicology, and neurotoxicity

5literature searchPubMedmethcathinone ephedrone manganese parkinsonism intravenous12 results, 11 selected
selection rationale

Critical safety data: IV methcathinone + manganese causes permanent parkinsonism

6literature searchPubMedmethcathinone dopamine transporter monoamine release transporter substrate7 results, 5 selected
selection rationale

Key transporter pharmacology data for methcathinone

7literature searchPubMedGlennon cathinone amphetamine drug discrimination rats stimulus generalization8 results, 3 selected
selection rationale

Foundational pharmacology papers; first characterization of methcathinone

8legal status searchWeb/DEA/UNODCmethcathinone Schedule I DEA 1992 emergency scheduling history United States legal status5 results, 2 selected
selection rationale

Essential legal scheduling data for multiple jurisdictions

9clinical trial searchClinicalTrials.govmethcathinone0 results
selection rationale

No trials to report

10literature searchPubMedmethcathinone drug discrimination locomotor stimulation amphetamine comparison rat1 result, 1 selected
11literature searchOpenAlexmethcathinone ephedrone neurotoxicity dopamine striatum PET8 results, 2 selected
12document retrievalDEA Federal Register via Erowidmethcathinone emergency scheduling 1992 19931 result, 1 selected
13legal status searchGOV.UK ACMDmethcathinone legal status UK history1 result, 1 selected
14database lookupOpenAlex/Crossref DOI verification10.1007/s13181-011-0193-z1 result, 1 selected
15literature searchPubMedcathinone methcathinone treatment addiction dependence therapy1 result, 1 selected
16document retrievalUNODC Substance Group Listingsynthetic cathinones methcathinone international control status1 result, 1 selected
17document retrievalGOV.UK ACMD Synthetic Cathinones Harms Assessmentmethcathinone UK legal status history pharmacology1 result, 3 selected
18web searchWebmethcathinone legal status UK Canada Australia Schedule controlled substance international10 results, 1 selected
Research document (raw, unedited pipeline output)
# Research Output: Methcathinone

**⚠️ Citation Correction Note:** Two citation numbers were corrected during final review:
- Habrat et al. 2013 is [Ref 44] (NOT Ref 18 — Ref 18 is Dal Cason et al. 1997)
- Liu & Zhao 2017 is [Ref 45] (NOT Ref 29 — Ref 29 is Selikhova et al. 2016)

---

## Chemical Identity

**PubChem CID:** 1576 (verified via API)
**IUPAC Name:** 2-(methylamino)-1-phenylpropan-1-one — confirmed, matches brief seed data
**Molecular Formula:** C₁₀H₁₃NO (verified via PubChem API)
**Molecular Weight:** 163.22 g/mol (verified via PubChem API)
**InChIKey:** LPLLVINFLBSFRP-UHFFFAOYSA-N (verified via PubChem API)
**Canonical SMILES:** CNC(C)C(=O)c1ccccc1 (derived from verified IUPAC structure; PubChem API did not return SMILES field directly — structural derivation only)
**CAS Number:** 5765-44-6 (standard in literature; not returned by API — FLAG for independent verification)
**Stereochemistry:** One chiral center at C-2. Two enantiomers: S(-)- and R(+)-methcathinone. Illicitly produced and sold primarily as the S(-) form, which is the more potent behavioral isomer (Glennon et al. 1995 [Ref 8]; Davies et al. 2020 [Ref 9]).

**Discrepancies with seed data:** Molecular formula, weight, and InChIKey were all blank in the brief — now confirmed from PubChem. SMILES was blank — now structurally derived from verified IUPAC name (flag for DB entry). PubChem CID was blank — now confirmed as 1576. No contradictions found with seed data.

---

## Pharmacology

### Mechanism of Action

Methcathinone is a **dopamine (DAT) and norepinephrine (NET) preferring monoamine transporter substrate** (releasing agent). It acts by entering presynaptic terminals via DAT and NET, then promoting carrier-mediated efflux (reverse transport) of dopamine and norepinephrine into the synapse — the same mechanism as amphetamine and methamphetamine (Glennon et al. 1987 [Ref 16]; Simmler et al. 2013 [Ref 7]; Davies et al. 2020 [Ref 9]).

Simmler et al. (2013 [Ref 7]) classified methcathinone into Group 1 cathinones (alongside cathinone and flephedrone) — agents that act as preferential DAT/NET uptake inhibitors and releasers, analogous to amphetamine/methamphetamine, in contrast to Group 2 (MDMA-like nonselective releasers) and Group 3 (cocaine-like pure reuptake inhibitors).

### Transporter Selectivity

- **NET:** Most potent target. Rothman et al. (2003 [Ref 2]) reported NET substrate activity with EC₅₀ ~50 nM for methcathinone.
- **DAT:** Nearly equipotent to NET as transporter substrate (Davies et al. 2020 [Ref 9]).
- **SERT:** ≥63-fold less potent than at DAT and NET (Davies et al. 2020 [Ref 9]). This high DAT/NET-to-SERT selectivity distinguishes methcathinone from MDMA-like entactogens and is a key predictor of its high abuse potential (Negus & Banks 2017 [Ref 22]).
- Simmler et al. (2013 [Ref 7]) confirmed methcathinone preferentially inhibits DA and NA uptake and induces DA release in transporter-transfected HEK293 cells.
- Eshleman et al. (2013 [Ref 26]) reported low affinity at dopamine receptors, high-nanomolar to mid-micromolar affinity at sigma-1 receptors, and low-potency partial agonism at 5-HT₁A, antagonism at 5-HT₂A, and weak antagonism at 5-HT₂C receptors. VMAT2 interactions are negligible.
- **TAAR1:** Cathinones (including methcathinone) do NOT act at TAAR1, unlike non-beta-keto amphetamines (Simmler et al. 2013 [Ref 7]).
- **Blood-brain barrier:** High permeability in vitro (Simmler et al. 2013 [Ref 7]).

### Enantiomers

The S(-) enantiomer is the primary active form sold illicitly and is more potent behaviorally: approximately twice as potent as S(+)-amphetamine and 3–5× more potent than R(+)-methcathinone in locomotor stimulation and drug discrimination assays (Glennon et al. 1995 [Ref 8]). The two enantiomers are nearly equieffective at DAT and NET as transporter substrates in vitro; the behavioral potency difference is not fully explained by transporter binding alone (Davies et al. 2020 [Ref 9]). S(-) was approximately twice as potent as R(+) in ICSS abuse potential measures (Davies et al. 2020 [Ref 9]).

### Potency Relative to Amphetamine

In amphetamine-trained drug discrimination, racemic methcathinone produced full generalization with ED₅₀ = 0.37 mg/kg (IP, rats) — more potent than racemic cathinone (0.71 mg/kg) or racemic amphetamine (0.71 mg/kg) (Glennon et al. 1987 [Ref 16]). S(-)-methcathinone: ED₅₀ = 0.11 mg/kg vs S(+)-methamphetamine ED₅₀ = 0.17 mg/kg (Young & Glennon 1998 [Ref 17]).

### In Vivo Neurochemistry

Glennon et al. (1987 [Ref 16]) demonstrated that methcathinone releases [³H]dopamine from rat caudate nucleus, similar to cathinone, amphetamine, and methamphetamine. In vivo microdialysis studies confirm dose-dependent increases in nucleus accumbens DA and 5-HT following methcathinone (Suyama et al. 2016 [Ref 20]; Cozzi et al. 2013 [Ref 23]). The ratio of DA-to-5-HT release selectivity positively correlates with abuse-related behavioral effects (Suyama et al. 2016 [Ref 20]).

### Pharmacokinetics

**No published human pharmacokinetic studies found.** This is a significant data gap.

Indirect animal/behavioral data:
- Onset: within 5 min (i.p. in rats; Young & Glennon 1998 [Ref 17])
- Duration of discriminative stimulus: approximately 60–90 minutes (rats, i.p.; Young & Glennon 1998 [Ref 17])
- Total clinical duration: estimated 4–6 hours (brief seed data; consistent with stimulant class but unverified by primary source)
- Metabolism: no published metabolic pathway data; no CYP enzyme involvement data found
- Urine detection: confirmed by GC-MS (Liu & Zhao 2017 [Ref 45]) and LC-Q/TOF methods (Glicksberg et al. 2016 [Ref 42])

**⚠️ FLAG (Safety-critical):** Dose data (threshold/light/common/strong/heavy ranges) in the seed data have no verifiable primary source. See Gaps & Flags.

---

## History

### First Synthesis and Early Medical Use

Methcathinone was **first synthesized in 1928** (attributed to work at Parke-Davis per UK ACMD report [Ref 38]). It was subsequently investigated as an **antidepressant in the former Soviet Union during the 1930s and 1940s** but not developed commercially (UK ACMD report [Ref 38]; Kelly 2011 [Ref 19]).

### Illicit Use Timeline

- **~1970s (USSR):** Methcathinone ("ephedrone" in Russian drug culture) began appearing as a drug of misuse. Illicit synthesis is straightforward: pseudoephedrine or ephedrine (available in cold remedies) is oxidized with potassium permanganate in acidic solution, yielding methcathinone hydrochloride contaminated with residual manganese compounds (Iqbal et al. 2012 [Ref 13]; Habrat et al. 2013 [Ref 44]; Sikk et al. 2011 [Ref 14]).
- **1987:** First published pharmacological characterization in Western literature by Glennon, Yousif, Naiman & Kalix [Ref 16].
- **Late 1980s–early 1990s:** Methcathinone appeared on the US clandestine drug market, with a documented epidemic primarily in **Michigan** (Glennon et al. 1995 [Ref 8]; Young & Glennon 1998 [Ref 17]).
- **May 1, 1992:** DEA placed methcathinone under temporary Schedule I emergency scheduling, citing imminent hazard to public safety (DEA 58 FR 25934 [Ref 31]).
- **April 29, 1993:** DEA extended temporary scheduling for 6 months (58 FR 25934 [Ref 31]).
- **1993:** Methcathinone HCl permanently placed in Schedule I of the Controlled Substances Act (no accepted medical use; high abuse potential; pharmacological effects similar to amphetamines) [Ref 31].
- **1971 Convention:** Methcathinone is listed in Schedule I of the 1971 UN Convention on Psychotropic Substances (UNODC [Ref 32]).
- **1990s–2010s (Eastern Europe, Baltic states):** Large-scale IV methcathinone epidemic in Estonia, Latvia, Ukraine, Poland, and other former Soviet states. IV preparations contaminated with residual manganese from permanganate synthesis caused a distinctive syndrome of manganese-induced parkinsonism (Refs 4, 12, 13, 14, 27, 28).

---

## Subjective Effects

**No controlled human studies of methcathinone's subjective effects have been published.** All characterization derives from animal behavioral research, clinical reports from abusers, and review literature.

### Animal Behavioral Data (Preclinical)

- Full generalization to methamphetamine, S(+)-amphetamine, cocaine, cathinone, aminorex, and methylphenidate in drug discrimination assays (Young & Glennon 1998 [Ref 17]; Glennon et al. 1995 [Ref 8]).
- Cocaine-like discriminative stimulus effects confirmed in rhesus monkeys (Smith et al. 2017 [Ref 36]).
- Robust locomotor stimulation in mice and rats (Glennon et al. 1987 [Ref 16]; Glennon et al. 1995 [Ref 8]).
- Dopamine antagonist haloperidol potently antagonizes the S(-)-methcathinone discriminative stimulus, implicating dopaminergic mechanism (Young & Glennon 1998 [Ref 17]).
- Abuse-related ICSS effects: both S(-) and R(+) forms facilitate ICSS; S(-) ~2× more potent (Davies et al. 2020 [Ref 9]).

### Human Clinical Literature (User/Patient Reports)

Per review literature (Debruyne et al. 2014 [Ref 33]; Kelly 2011 [Ref 19]; Prosser & Nelson 2011 [Ref 37]):
- **Desired effects:** increased energy, euphoria, confidence, reduced fatigue, increased sociability, improved libido
- **Cardiovascular:** tachycardia, hypertension, vasoconstriction (class effect, documented in stimulant users)
- **Psychiatric (adverse):** agitation, anxiety, paranoia, hallucinations with heavy/chronic use
- **Stimulant syndrome:** bruxism, excessive sweating, anorexia, insomnia, compulsive redosing

### Effects Taxonomy (from brief) — Literature Support Assessment

The following effect categories from the brief's taxonomy are assessed against the literature:
- **Motivation enhancement, focus enhancement, thought acceleration, cognitive euphoria:** Supported at class level (amphetamine/DA-mechanism); no methcathinone-specific human study.
- **Stimulation, wakefulness, vasoconstriction, abnormal heartbeat, excessive sweating, bruxism, dehydration:** Cardiovascular/sympathomimetic effects documented in clinical case reports and review literature.
- **Anxiety, paranoia, irritability:** Documented as adverse effects in clinical literature (Debruyne et al. 2014 [Ref 33]).
- **Compulsive redosing urge:** Strongly supported by Eastern European epidemic literature (Myśliwka et al. 2011 [Ref 15]; Kelly 2011 [Ref 19]).
- **Anhedonia, depression:** Consistent with stimulant crash/withdrawal; not specifically studied for methcathinone.

### Duration

- Discriminative stimulus (rats, i.p.): ~60–90 min (Young & Glennon 1998 [Ref 17])
- Total clinical duration estimate: 4–6 hours oral (brief seed data; unverified by primary human source)
- IV: faster onset, potentially more intense but duration data not found

---

## Safety & Toxicity

### Acute Toxicity (Animal Data)

- **LD₅₀ (mouse, i.p., pure methcathinone):** 201.7 mg/kg (Asser et al. 2019 [Ref 10])
- **LD₅₀ (mouse, i.p., pseudoephedrine+permanganate mixture):** 110.2 mg Mcat-equivalent/kg — substantially lower, reflecting additive toxicity from manganese (Asser et al. 2019 [Ref 10])
- High doses: epileptic seizures in 74% of mice; dose-dependent mortality (Asser et al. 2019 [Ref 10])
- Stimulant doses (10–25 mg/kg i.p.): clear dose-dependent motor activity stimulation (Asser et al. 2019 [Ref 10])
- **No human LD₅₀ data. No therapeutic index data. ⚠️ FLAG: Safety-critical gap.**

### Dopaminergic and Serotonergic Neurotoxicity

- Both R(+) and S(-) enantiomers damage dopamine neurons (DA axonal markers, silver degeneration) in mice and rats (Sparago et al. 1996 [Ref 5])
- S(-)-methcathinone additionally damages serotonin neurons in rats — R(+) does not; N-methylation is the structural determinant conferring 5-HT neurotoxicity absent from cathinone itself (Sparago et al. 1996 [Ref 5])
- Neurotoxicity is species- and enantiomer-dependent (Sparago et al. 1996 [Ref 5])

**Human PET evidence (the only human-specific neurotoxicity data):**
McCann et al. (1998 [Ref 6]) performed PET imaging in 4 abstinent methcathinone users (mean ~3 years abstinence):
- 24% reduction in caudate DAT density vs controls
- 16% reduction in putamen DAT density vs controls
- No clinical parkinsonism observed at time of study
- Authors raised possibility of increased future parkinsonism risk as these individuals age

Note: Small sample (n=4); no longitudinal follow-up published for these specific subjects.

**Prefrontal cortex (rat, 2025):**
2-week methcathinone exposure (0.25–20 mg/kg i.p.) caused learning/memory decline and synaptic structural damage in PFC (Zhou et al. 2025 [Ref 3]). Transcriptomics identified 1,457 DEGs; key genes: DRD1, DRD2, SLC1A2, CAMK2A, SYT1, GRIN2A, NGF (Zhou et al. 2025 [Ref 3]).

### Manganism from IV Use — Primary Clinical Hazard

The most extensively documented safety hazard of methcathinone is **manganese encephalopathy from IV use of illicitly synthesized preparations**. Potassium permanganate is the oxidant in the clandestine synthesis route, leaving residual manganese (Mn) in the product; chronic IV injection of this preparation deposits Mn in the brain, causing permanent, levodopa-resistant parkinsonism.

**Clinical syndrome (IV use, contaminated preparation):**
- Hypokinesia, dystonia, postural instability, freezing gait (Sikk et al. 2011 [Ref 14])
- Characteristic dysarthria/hypophonia (Selikhova et al. 2016 [Ref 29])
- Extrapyramidal: tremor, rigidity, retro/propulsion, micrographia
- Onset within months of regular IV use (Iqbal et al. 2012 [Ref 13]; Habrat et al. 2013 [Ref 44])
- Documented across Eastern Europe and Baltic states: Estonia, Latvia, Ukraine, Poland, Ireland (Sikk et al. 2013 [Ref 12]; Stepens et al. 2014 [Ref 28])

**Neuroimaging:**
- Bilateral globus pallidus hyperintensity on T1-weighted MRI — characteristic and diagnostically useful (Juurmaa et al. 2016 [Ref 11])
- Diffuse white matter damage: decreased fractional anisotropy on DTI; worst in ventral premotor and medial frontal cortex (Stepens et al. 2010 [Ref 27])
- Grey matter volume abnormalities (Juurmaa et al. 2016 [Ref 11])

**Distinguishing from idiopathic Parkinson's disease:**
- Mn-induced parkinsonism does NOT involve midbrain dopamine neuron degeneration (Guilarte 2010 [Ref 43])
- **L-DOPA is NOT an effective treatment** — a key diagnostic distinction (Sikk et al. 2011 [Ref 14]; Guilarte 2010 [Ref 43])
- Chelation therapy generally ineffective (Habrat et al. 2013 [Ref 44])

**Outcome:**
- Movement disorder largely permanent and progressive; long-term prognosis poor (Stepens et al. 2014 [Ref 28])
- Parkinsonian features in approximately half of long-term IV users (Golasik et al. 2014 [Ref 41])
- Manganese elevated in urine in ~29% of methcathinone users (Golasik et al. 2014 [Ref 41])

**Cognitive/neuropsychological effects (IV population):**
- Increased reflection impulsivity despite superficially intact routine cognition (Djamshidian et al. 2013 [Ref 4])
- Neuropsychological deficits in 16-patient case series with manganese encephalopathy (Kałwa 2020 [Ref 30])
- Measurable cognitive impairment on detailed neuropsychometric testing in 9 patients (Koksal et al. 2014 [Ref 39])

---

## Harm Reduction

No published harm reduction protocols specific to methcathinone were found. The following derives from class evidence and the clinical literature on manganism:

1. **IV administration is extremely high risk** and strongly contraindicated due to manganism. Illicit synthesis with potassium permanganate inevitably introduces Mn contamination; no home synthesis method avoids this risk (Iqbal et al. 2012 [Ref 13]; Asser et al. 2019 [Ref 10]).

2. **Oral or insufflation** carry substantially lower acute neurological risk but still carry cardiovascular and dependence risks.

3. **Testing:** Methcathinone can be detected in urine and blood via LC-Q/TOF or GC-MS (Glicksberg et al. 2016 [Ref 42]; Liu & Zhao 2017 [Ref 45]). No field reagent test (colorimetric) data found in published literature.

4. **Overdose management:** No specific antidote exists. Management extrapolated from amphetamine/cocaine overdose: benzodiazepines for seizures/agitation, active cooling for hyperthermia, IV fluids (Debruyne et al. 2014 [Ref 33]; Prosser & Nelson 2011 [Ref 37]).

5. **Contraindications (class inference; no methcathinone-specific study):**
   - MAOIs — risk of hypertensive crisis/serotonin syndrome (⚠️ FLAG: no substance-specific evidence)
   - Other stimulants — additive cardiovascular toxicity
   - Cardiovascular disease, hypertension, arrhythmia
   - History of psychosis or schizophrenia

---

## Tolerance & Dependence

### Dependence

Dependence documented in case reports and Eastern European epidemic literature:
- Case report: 32-year-old patient addicted to IV ephedrone for 3 years (Myśliwka et al. 2011 [Ref 15])
- Described as cheaper, more accessible than amphetamine; driving adoption among stimulant-seeking populations (Myśliwka et al. 2011 [Ref 15])
- Pattern of compulsive IV use with tolerance escalation documented throughout Eastern European literature

### Tolerance (Preclinical Data Only)

In rat ICSS studies, repeated methcathinone treatment resulted in complex tolerance and sensitization dynamics (Suyama et al. 2019 [Ref 21]). No published human clinical tolerance studies found.

### Withdrawal

No published human withdrawal syndrome characterization for methcathinone specifically. Expected stimulant withdrawal profile by class (fatigue, anhedonia, depression, hypersomnia) — not substance-specific data.

### Cross-Tolerance

Expected cross-tolerance with amphetamine, methamphetamine, and other DAT/NET releasing agents. Full drug discrimination generalization between methcathinone and amphetamine/methamphetamine supports this (Young & Glennon 1998 [Ref 17]). No published substance-specific cross-tolerance study.

---

## Interactions

**No published drug interaction studies specific to methcathinone.** All below is class-level pharmacological inference. ⚠️ FLAG: All interaction data requires human review.

- **MAOIs:** Highly contraindicated. Monoamine releasing agent + MAOI = dangerous elevation of synaptic monoamines: risk of hypertensive crisis, hyperthermia, seizures, death.
- **Other stimulants (amphetamine, cocaine, MDMA):** Additive/synergistic cardiovascular and thermic effects.
- **Serotonergic drugs (SSRIs, SNRIs, triptans):** Methcathinone releases 5-HT in vivo (Suyama et al. 2016 [Ref 20]; Cozzi et al. 2013 [Ref 23]); serotonin syndrome risk is plausible, though no substance-specific study exists.
- **Antidepressants (TCAs, SNRIs):** May amplify cardiovascular sympathomimetic effects.
- **Haloperidol/D2 antagonists:** Haloperidol potently antagonizes methcathinone's discriminative stimulus in rats (Young & Glennon 1998 [Ref 17]); not clinically validated as antidote.

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Source |
|---|---|---|---|
| United States | Illegal | Schedule I, CSA | Temp: May 1992; Permanent: 1993 [Ref 31] |
| International | Controlled | Schedule I, 1971 UN Convention on Psychotropic Substances | [Ref 32] |
| United Kingdom | Illegal | Class B, Schedule 1 MDR 2001 | [Ref 38] |
| Australia | Prohibited | Schedule 9, Poisons Standard | Web-retrieved |
| Canada | Controlled | CDSA Schedule | Web-retrieved |
| European Union | Controlled | Most states: Schedule I equivalent under 1971 Convention | [Ref 32] |

---

## Clinical Trials

No clinical trials involving methcathinone found on ClinicalTrials.gov. Search conducted May 2026. No registered trials as intervention, comparator, or subject of study.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### ⚠️ Safety-Critical Flags

1. **Dose ranges (not verified):** The brief's dose data (Threshold 25 mg, Light 50–100 mg, Common 100–200 mg, Strong 200–300 mg, Heavy 300+ mg, oral) have **no verifiable primary source** in the published literature. No controlled human dosing studies for methcathinone exist. These values are stated in the brief as inferred. They are broadly plausible given methcathinone's ~2× potency over amphetamine in rat drug discrimination, but must be flagged for editorial review before publication. Do NOT present as established data.

2. **Duration data:** The 4–6 hour total oral duration from the brief lacks a primary source. Only published duration data: ~60–90 min discriminative stimulus in rats (i.p., Young & Glennon 1998). Total human duration consistent with class but unverified.

3. **Human pharmacokinetics: entirely absent.** Half-life, Tmax, bioavailability, plasma protein binding, CYP metabolism, and volume of distribution are unknown from published data. Generation agent must not make specific PK claims.

4. **Interaction data: all class inference.** No methcathinone-specific drug interaction studies found. All interaction statements require clear sourcing as extrapolated.

5. **ROA discrepancy:** Brief lists oral as primary/only ROA. Published literature documents IV as the predominant route in epidemic populations (Eastern Europe). Insufflation is also common per reviews. This is a meaningful discrepancy — real-world use does not match seed data. Requires editorial review.

### Data Absent from Literature

- Human pharmacokinetics
- Specific drug interaction studies
- Published harm reduction protocols
- Withdrawal syndrome characterization (human)
- CAS number (literature 5765-44-6 — not API-verified)
- SMILES (structurally derived; not API-returned)
- Physical properties: melting point, solubility, stability — not found

### Sections Based on Structural Analogy / Class Inference Only

- **All interactions:** Class-level pharmacology
- **All contraindications:** Class-level inference
- **Withdrawal syndrome:** Extrapolated from stimulant class
- **Tolerance:** Only rat ICSS data; no human clinical data
- **Brief toxicity assessment note confirmed:** Brief states "Inferred from pharmacological class." Actual toxicity warrants upgrading to HIGH RISK (moderate acute, severe chronic via manganism with IV use, and persistent DAT loss documented by PET).

### Source Quality Notes

- Manganism literature (Refs 4, 11–15, 27–30, 39–41, 44): robust (multiple cohort studies, neuroimaging, neuropathology) but specific to IV use with permanganate-contaminated preparations — not intrinsic to pure methcathinone
- Foundational pharmacology (Refs 2, 7, 9, 16, 17, 20): high quality but conducted in rodents or cell cultures
- Only human in vivo neurotoxicity evidence: McCann et al. 1998 [Ref 6] — n=4 methcathinone users; small sample
- No controlled human dose/effect studies exist for this substance